GVP and PV Quality Systems: What Regulators Expect Beyond the PSMF GVP and PV Quality Systems: What Regulators Expect Beyond the PSMF In today’s complex regulatory landscape, establishing robust pharmacovigilance (PV) systems and understanding Good Vigilance Practice (GVP) quality systems are vital for pharma and biotech organizations. These regulations are pivotal not only for compliance but also for ensuring patient safety. This article serves as a comprehensive regulatory explainer manual for professionals in Regulatory Affairs, CMC, and Labelling teams, elucidating the legal framework, documentation requirements, review processes, and common pitfalls regarding GVP and PV quality systems. Regulatory Context Pharmacovigilance revolves…

Designing a PV QMS That Integrates Smoothly with Corporate Quality Designing a PV QMS That Integrates Smoothly with Corporate Quality Pharmacovigilance (PV) is a critical component of drug development and life cycle management, focusing on the detection, assessment, and prevention of adverse effects or any other drug-related problems. The interconnectedness of service pharmacovigilance with corporate quality systems underlines the necessity for a robust PV Quality Management System (QMS) that not only adheres to regulatory requirements but also allows seamless integration with other quality systems established across the organization. This article aims to provide a comprehensive regulatory explainer manual for implementing…

Signal, Case Processing and Aggregate Reporting: Quality Checks That Matter Signal, Case Processing and Aggregate Reporting: Quality Checks That Matter Regulatory Affairs Context Pharmacovigilance is a critical aspect of drug safety and efficacy monitoring post-marketing and clinical usage. In Regulatory Affairs (RA), the integration of Good Pharmacovigilance Practices (GVP) and Good Manufacturing Practices (GMP) is essential for maintaining compliance with applicable regulatory requirements across jurisdictions such as the US, EU, and UK. This article provides an in-depth exploration of regulatory expectations related to pharmacovigilance services, focusing specifically on signal detection, case processing, and aggregate reporting. Legal/Regulatory Basis The legal framework…

Using PV Audits and Inspections to Strengthen System Design Using PV Audits and Inspections to Strengthen System Design Regulatory Affairs Context Regulatory Affairs professionals play a crucial role in ensuring that pharmaceutical and biotechnology companies adhere to a complex framework of legal and regulatory requirements. This article focuses on the integration of Pharmacovigilance (PV) audits and inspections as a means to enhance Quality Systems in compliance with Good Pharmacovigilance Practice (GVP) guidelines across the US, UK, and EU. The struggle for regulatory compliance has increased the demand for effective quality management systems, making it imperative for organizations to understand the…

Handling Deviations, Quality Issues and CAPA in PV Operations Handling Deviations, Quality Issues and CAPA in PV Operations Context In the realm of global pharmacovigilance (PV), the need to manage deviations, quality issues, and corrective and preventive actions (CAPA) is paramount. The integration of GxP quality systems within regulatory affairs is crucial for ensuring that pharmaceutical products are safe, effective, and compliant with applicable regulations. Regulatory authorities in the US (FDA), EU (EMA), and UK (MHRA) emphasize the importance of robust quality systems, expecting pharmaceutical companies to actively monitor and manage quality-related issues throughout the lifecycle of their products. Legal/Regulatory…

Data Integrity and Documentation Principles in Safety Systems Data Integrity and Documentation Principles in Safety Systems Regulatory Affairs Context In the pharmaceutical industry, the integrity of data and the thoroughness of documentation are paramount, especially in safety systems governed by Good Pharmacovigilance Practices (GVP). Regulatory authorities across the globe, including the FDA, European Medicines Agency (EMA), and the Medicines and Healthcare products Regulatory Agency (MHRA), have established stringent regulations and guidelines that dictate the standards required for the safe and effective management of pharmaceutical products. This article aims to elucidate these principles and the regulatory expectations behind them. Legal and…

Vendor and Partner Oversight in PV: Contracts, SLAs and QA Samples Vendor and Partner Oversight in PV: Contracts, SLAs and QA Samples In the complex landscape of pharmaceutical development and commercialization, ensuring compliance with regulatory standards is paramount. Regulatory Affairs (RA) professionals play a vital role in this ecosystem, particularly in the oversight of vendors and partners involved in Pharmacovigilance (PV). This article explores the regulatory expectations surrounding vendor and partner oversight, with a focus on contracts, Service Level Agreements (SLAs), and Quality Assurance (QA) samples. Context Vendor and partner oversight in PV is critical for maintaining the integrity of…

Case Studies: PV QMS Failures That Led to Enforcement Actions Case Studies: PV QMS Failures That Led to Enforcement Actions In the pharmaceutical industry, regulatory compliance and quality management systems (QMS) are critical to ensuring the safety and efficacy of products. This is especially true in the realm of pharmacovigilance (PV), where the primary focus is monitoring the safety of pharmaceutical products and ensuring that any adverse events are reported accurately and promptly. However, failures in PV QMS can lead to serious consequences, including regulatory enforcement actions. This article examines regulatory guidelines, agency expectations, significant case studies, and best practices…

Linking PV CAPA and Findings to Label Changes and Regulatory Updates Linking PV CAPA and Findings to Label Changes and Regulatory Updates Context: Regulatory Affairs in Pharmacovigilance Regulatory Affairs (RA) plays a pivotal role in ensuring that pharmacovigilance (PV) activities comply with local and international regulations. As regulations and best practices evolve, the integration of Good Pharmacovigilance Practices (GVP) with Capas (Corrective and Preventive Actions) management becomes essential. This article outlines the critical interplay between CAPA findings, labeling changes, and subsequent regulatory updates, specifically addressing the compliance regulatory affairs that govern these processes. Legal and Regulatory Basis Understanding the regulatory…

Governance Committees for PV Quality and Risk Oversight Governance Committees for PV Quality and Risk Oversight In an increasingly regulated pharmaceutical landscape, the integration of governance committees within pharmacovigilance (PV) quality systems has emerged as essential for ensuring regulatory affairs compliance. This article offers a comprehensive review of the role that governance committees play, the legal framework that supports their function, and best practices that can be adopted to enhance the robustness of PV quality oversight. Context Pharmacovigilance is a critical element of the drug development continuum, providing essential data on the safety and efficacy of pharmaceuticals once they are…